Diranersen Slows Alzheimer’s Progression by Up to 42%
Recent clinical data indicates that Diranersen, a targeted antisense oligonucleotide therapy, may slow cognitive decline in Alzheimer’s patients by up to 42%. This breakthrough, emerging from recent trial results, targets ... Read More